Neumora Therapeutics (NMRA) Share-based Compensation (2022 - 2026)

Neumora Therapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 20.58% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $28.0 million, a 61.19% decrease from a year earlier, with the FY2025 full-year figure at $35.0 million, down 12.48% from the prior year.
• Share-based Compensation steadied at $7.4 million in Q1 2026 per NMRA's latest filing, from $7.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $40.0 million in Q4 2024 and bottomed at $2.1 million in Q3 2022.
• The 5-year median for Share-based Compensation is $7.3 million (2024), against an average of $8.8 million.
• Across the five-year window, Share-based Compensation jumped 560.88% in 2024 and plunged 81.48% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $2.8 million in 2022, then soared by 116.73% to $6.1 million in 2023, then soared by 560.88% to $40.0 million in 2024, then plunged by 81.48% to $7.4 million in 2025, then declined by 0.03% to $7.4 million in 2026.
• Per Business Quant, the three latest NMRA Share-based Compensation figures stand at $7.4 million (Q1 2026), $7.4 million (Q4 2025), and $6.0 million (Q3 2025).